Accelr8 Begins Private Equity Sale to Address 'Going Concern' | GenomeWeb

NEW YORK (GenomeWeb News) – Accelr8 said today that it has begun a private sale of equity to qualified investors. The company first announced the equity offer following its annual shareholders' meeting on Dec. 16.

Accler8 also provided updates on several recent corporate events, including that of a "going concern" statement by its auditors attributed to recurring losses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.